<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: &lt;i&gt;BMPR1A&lt;/i&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: <i>BMPR1A</i></h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: <i>BMPR1A</i></div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Chung, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kiley Delgado, MS, CGC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Thomas Lamont, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne Slavotinek, MBBS, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 16, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4041220039"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph summarizes the interpretation of germline testing of the<em> BMPR1A </em>gene. It does <strong>not</strong> discuss indications for testing and is not intended to replace clinical judgment in the decision to test or the care of the tested individual. These subjects are discussed separately [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H1739972011"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H2518413620"><span class="h2">How to read the report</span><span class="headingEndMark"> — </span>An approach to reviewing a genetic test report is summarized in the checklist  (<a class="graphic graphic_table graphicRef122437" href="/d/graphic/122437.html" rel="external">table 1</a>). </p><p>Testing involves two steps: determining the genotype and interpreting the pathogenicity of the variant(s).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Determining the</strong> <strong>genotype</strong> – Identifies variants. Should be repeated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (or other nationally certified laboratory) if the results were obtained by direct-to-consumer testing or a research study and would impact clinical care (eg, positive finding, negative finding in an individual with a suspected juvenile polyposis syndrome [JPS]). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong> – Determines pathogenicity of the variants identified. May require updating, especially for variants of uncertain significance (VUS). </p><p></p><p>The table provides a glossary of genetic testing terms  (<a class="graphic graphic_table graphicRef122429" href="/d/graphic/122429.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H1909884165"><span class="h2">Disease associations</span><span class="headingEndMark"> — </span>Pathogenic and likely pathogenic variants in <em>BMPR1A</em> cause JPS, an autosomal dominant disorder.</p><p>The <em>BMPR1A</em> (<em>ALK3</em>) gene is located on chromosome 10q22-23 and encodes a serine/threonine kinase receptor protein that is also involved in the transforming growth factor-beta (TGF-beta) signaling pathway. Upon activation, <em>BMPR1A</em> phosphorylates SMAD family proteins.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intestinal tumors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>JPS is characterized by the presence of multiple juvenile polyps of the colorectum. Most patients are symptomatic by age 20 years. Rectal bleeding is the most common presenting symptom. Other symptoms include abdominal pain due to obstruction from intussusception, diarrhea due to protein-losing enteropathy, and rectal prolapse of polyps. </p><p></p><p>Polyps usually begin to appear in the first decade of life, and patients can develop between five to hundreds of polyps in their lifetime. Polyps occur predominantly in the colorectum but can occur in the stomach, duodenum, jejunum, and ileum. </p><p class="bulletIndent2">Individuals with JPS are at increased risk for colorectal, small bowel, and gastric cancer. Though lifetime risk for colorectal cancer has been difficult to estimate, a review of a large JPS kindred (117 members) provided an estimate of a 50 percent risk of gastrointestinal malignancy [<a href="#rid2">2</a>]. In a separate review of 218 patients with juvenile polyposis, malignancy developed in 17 percent of patients. The mean age of cancer diagnosis in this sample was 33.5 [<a href="#rid3">3</a>]. The Brosens article (GUT 2007) has relative risk (RR) for colorectal cancer of 34 with mean age of colorectal cancer of 44 years (± 10.4 years) and lifetime risk of 38.7 percent [<a href="#rid4">4</a>]. The Blatter reference (Genetics in Medicine, 2020) says median age of colorectal cancer is 38 years (range 19 to 67 years) [<a href="#rid5">5</a>]. Individuals with JPS are also at increased risk for gastric and duodenal cancer, with an estimated lifetime risk of 11 to 20 percent. </p><p></p><p class="bulletIndent1">Juvenile polyposis of infancy is a rare variant of JPS in which juvenile (hamartomatous) polyps occur in both the upper and lower gastrointestinal tract (including the small bowel) and polyps develop within the first few years of life. In the stomach, juvenile polyps can be more difficult to recognize and often resemble hyperplastic polyps or other hamartomatous gastric polyps. Symptoms include diarrhea, bleeding, and intussusception. Macrocephaly and hypotonia may also occur, and patients often die at an early age due to complications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extraintestinal manifestations</strong> – Other rare conditions associated with JPS include congenital cardiac (eg, mitral valve prolapse), vascular (eg, arterial aneurysms), skeletal, and cranial abnormalities [<a href="#rid6">6</a>].</p><p></p><p class="headingAnchor" id="H4268251837"><span class="h1">IMPLICATIONS OF A PATHOGENIC OR LIKELY PATHOGENIC VARIANT</span><span class="headingEndMark"> — </span>We consider all individuals with a pathogenic or likely pathogenic variant in <em>BMPR1A</em> to be at risk for juvenile polyposis syndrome (JPS), regardless of the initial reason for testing.</p><p>Discussion should include the range of associated risks, possible interventions for surveillance or risk reduction, and implications for family members. Counseling may require additional visits or referrals. (See <a class="local">'At-risk relatives'</a> below.)</p><p>We adhere to National Comprehensive Cancer Network (NCCN) recommendations for cancer surveillance and risk reduction [<a href="#rid7">7</a>]. Findings in family members (type of cancers, age of onset) may also inform surveillance (starting at an earlier age if a family member has an earlier age of onset). </p><p>In addition to annual physical examination including a cardiovascular examination, we monitor a complete blood count annually to evaluate for iron deficiency anemia secondary to blood loss. Several evaluations and interventions are recommended to reduce the risk of JPS-associated cancers. However, data on whether these evaluations impact outcomes or survival are lacking  (<a class="graphic graphic_algorithm graphicRef130812" href="/d/graphic/130812.html" rel="external">algorithm 1</a>). </p><p class="headingAnchor" id="H886916105"><span class="h2">Colorectal polyps and cancer</span></p><p class="bulletIndent2"><span class="glyph">•</span>Colorectal cancer screening/surveillance:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Individuals with a pathogenic<em> BMPR1A </em>variant should have a colonoscopy every one to three years, beginning at age 12 years or earlier in patients who present with symptoms. If polyps are found, colonoscopy should be repeated annually; otherwise, colonoscopy intervals can be performed every one to three years [<a href="#rid8">8</a>]. Polyps can usually be resected endoscopically.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Indications for colectomy and ileorectal anastomosis (IRA) or proctocolectomy and ileal pouch anal anastomosis include: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Severe symptoms related to colonic polyps (eg, severe gastrointestinal bleeding)</p><p class="bulletIndent3"><span class="glyph">-</span>Colorectal cancer, adenoma with high-grade dysplasia or multiple adenomas &gt;6 mm </p><p class="bulletIndent3"><span class="glyph">-</span>Marked increases in polyp number on consecutive examinations</p><p class="bulletIndent3"><span class="glyph">-</span>Inability to adequately survey the colon because of multiple polyps</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Following colectomy, continued endoscopic evaluation of the rectum and ileal pouch every 12 months. </p><p></p><p class="headingAnchor" id="H576318582"><span class="h2">Upper gastrointestinal tract polyps and cancer</span></p><p class="bulletIndent1"><span class="glyph">●</span>Upper endoscopy starting at the age of 12 years. If polyps are detected, upper endoscopy is repeated annually. In the absence of upper gastrointestinal tract polyps, upper endoscopy can be performed every two to three years [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Baseline examination of the small bowel starting in the teenage years and then repeated periodically based upon the presence of small bowel polyps or symptoms, including anemia or protein-losing enteropathy. The small bowel can be evaluated using wireless capsule endoscopy, small bowel imaging, or small bowel enteroscopy (eg, double balloon enteroscopy). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with advanced dysplasia, gastric cancer, or massive gastric polyposis that cannot be effectively managed endoscopically, complete or partial gastrectomy is warranted.</p><p></p><p class="bulletIndent1">Additional details and supporting evidence are discussed separately. (See  <a class="medical medical_review" href="/d/html/15805.html" rel="external">"Juvenile polyposis syndrome", section on 'Management'</a>.)</p><p></p><p class="headingAnchor" id="H3279662019"><span class="h1">IMPLICATIONS OF A NEGATIVE TEST</span><span class="headingEndMark"> — </span>Negative testing means no pathogenic variants were identified  (<a class="graphic graphic_algorithm graphicRef130812" href="/d/graphic/130812.html" rel="external">algorithm 1</a>). In approximately one-half of patients with clinical features of juvenile polyposis syndrome (JPS), no pathogenic variants are found in <em>BMPR1A</em> or <em>SMAD4</em>. These individuals tend to be younger in age, have a lower risk of colectomy, and do not exhibit gastric/duodenal polyposis [<a href="#rid9">9</a>]. However, some tests only evaluate a subset of variants; pathogenic variants might be present in other parts of the gene (if testing was not comprehensive) or in other genes (eg, <em>SMAD4</em>).</p><p class="bulletIndent1"><span class="glyph">●</span>If a familial <em>BMPR1A</em> variant is known and the tested individual does not have that variant, usually they can be reassured that they are not at high risk for juvenile polyposis syndrome (JPS), with caveats outlined above (see <a class="local">'How to read the report'</a> above). However, it is important to provide an individualized risk assessment based on family history and other risk factors. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a familial <em>BMPR1A</em> variant is not known and the results of genetic testing are negative, the extent of additional testing depends on the personal and family history. Referral to a clinical geneticist, oncologist, or genetic counselor may be helpful to determine optimal testing in those with a strong family history of gastrointestinal polyposis or telangiectasia. (See <a class="local">'Locating a genetics expert'</a> below.)</p><p></p><p class="headingAnchor" id="H1854062717"><span class="h1">IMPLICATIONS OF A VUS</span><span class="headingEndMark"> — </span>Individuals with a variant of uncertain significance (VUS) should be managed based on their personal and family history and not the VUS  (<a class="graphic graphic_algorithm graphicRef130812" href="/d/graphic/130812.html" rel="external">algorithm 1</a>).</p><p>New information may become available; the testing laboratory or other resources should be consulted periodically for updates (eg, annually). </p><p>The implications of genetic test results should be discussed with the individual's gastroenterologist, oncologist, or surgeon; in some cases, referral to a specialist in hereditary colorectal cancer syndromes may be appropriate. </p><p class="headingAnchor" id="H3813654140"><span class="h1">CONSIDERATIONS FOR FAMILY MEMBERS</span></p><p class="headingAnchor" id="H3345812798"><span class="h2">Reproductive counseling</span><span class="headingEndMark"> — </span>Family planning is appropriate for individuals with a pathogenic or likely pathogenic variant in <em>BMPR1A </em>who are considering childbearing.</p><p>Some may elect assisted reproduction (including donor gametes or in vitro fertilization [IVF] with preimplantation genetic testing [PGT]) or prenatal diagnosis. (See  <a class="medical medical_review" href="/d/html/6783.html" rel="external">"Preimplantation genetic testing", section on 'Patients known to be at increased risk of offspring with a specific medically actionable condition'</a>.)</p><p class="headingAnchor" id="H2943936826"><span class="h2">At-risk relatives</span><span class="headingEndMark"> — </span>Individuals with a pathogenic variant or likely pathogenic variant in <em>BMPR1A </em>should inform their at-risk relatives about the importance of genetic counseling and possible testing.</p><p class="bulletIndent1"><span class="glyph">●</span>The risk of inheriting or having the variant is typically 50 percent for first-degree relatives. Others at risk may include aunts, uncles, nieces, nephews, and cousins. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Usually, the variant segregates on the side of the family with a history of polyposis or gastrointestinal cancer; however, if possible, it is recommended to test a parent or other relative with cancer. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic testing of at-risk relatives may be considered as early as 12 years. Age of polyposis onset for relatives may help guide the timing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Families facing decisions to test minors should meet with a genetic counselor or other health care provider with genetics expertise. If genetic testing is deferred in a child at 50 percent risk, juvenile polyposis syndrome (JPS) screening is recommended until genetic testing is obtained for a more precise estimation of recurrence risk. (See  <a class="medical medical_review" href="/d/html/2901.html" rel="external">"Genetic testing", section on 'Ethical, legal, and psychosocial issues'</a> and <a class="local">'Implications of a pathogenic or likely pathogenic variant'</a> above.)</p><p></p><p class="headingAnchor" id="H2365857552"><span class="h1">RESOURCES</span></p><p class="headingAnchor" id="H101301899"><span class="h2">UpToDate topics</span></p><p class="bulletIndent1"><span class="glyph">●</span>Juvenile polyposis syndrome (JPS):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Manifestations, cancer risks, and management – (See  <a class="medical medical_review" href="/d/html/15805.html" rel="external">"Juvenile polyposis syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetics:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Variant classification – (See  <a class="medical medical_review" href="/d/html/2900.html" rel="external">"Basic genetics concepts: DNA regulation and gene expression", section on 'Clinical classification of pathogenicity'</a>.) </p><p class="bulletIndent2"><span class="glyph">•</span>Terminology – (See  <a class="medical medical_review" href="/d/html/2898.html" rel="external">"Genetics: Glossary of terms"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic testing – (See  <a class="medical medical_review" href="/d/html/2901.html" rel="external">"Genetic testing"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic counseling – (See  <a class="medical medical_review" href="/d/html/103304.html" rel="external">"Genetic counseling: Family history interpretation and risk assessment"</a>.)</p><p></p><p class="headingAnchor" id="H1134361709"><span class="h2">Locating a genetics expert</span></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical geneticists – American College of Medical Genetics and Genomics (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=130281" target="_blank">ACMG</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic counselors – National Society of Genetic Counselors (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflwwaDFffULns7AVKZBF0Vtm&amp;TOPIC_ID=130281" target="_blank">NSGC</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>National Institutes of Health (NIH) Cancer Genetics <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Fcauses-prevention%2Fgenetics%2Fdirectory&amp;token=j%2Fp%2BIZfImoJgnd%2Fk4T5MAbDlZmLADFk1VrVOJqDdPzf1mGWFw3YadpFlBYSMxNKDeExYMR0QNQoNISFKbh7RPtm%2BfHLonSi2ZDCqhRzTq0w%3D&amp;TOPIC_ID=130281" target="_blank">Services Directory</a> </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li><a class="nounderline abstract_t">Howe JR, Mitros FA, Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 1998; 5:751.</a></li><li><a class="nounderline abstract_t">Coburn MC, Pricolo VE, DeLuca FG, Bland KI. Malignant potential in intestinal juvenile polyposis syndromes. Ann Surg Oncol 1995; 2:386.</a></li><li><a class="nounderline abstract_t">Brosens LA, van Hattem A, Hylind LM, et al. Risk of colorectal cancer in juvenile polyposis. Gut 2007; 56:965.</a></li><li><a class="nounderline abstract_t">Blatter R, Tschupp B, Aretz S, et al. Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers. Genet Med 2020; 22:1524.</a></li><li><a class="nounderline abstract_t">Heald B, Rigelsky C, Moran R, et al. Prevalence of thoracic aortopathy in patients with juvenile Polyposis Syndrome-Hereditary Hemorrhagic Telangiectasia due to SMAD4. Am J Med Genet A 2015; 167A:1758.</a></li><li class="breakAll">https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf (Accessed on October 24, 2022).</li><li><a class="nounderline abstract_t">Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015; 110:223.</a></li><li><a class="nounderline abstract_t">MacFarland SP, Ebrahimzadeh JE, Zelley K, et al. Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A Variant. Cancer Prev Res (Phila) 2021; 14:215.</a></li></ol></div><div id="topicVersionRevision">Topic 130281 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9869523" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The risk of gastrointestinal carcinoma in familial juvenile polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7496832" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Malignant potential in intestinal juvenile polyposis syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17303595" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Risk of colorectal cancer in juvenile polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32398773" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25931195" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence of thoracic aortopathy in patients with juvenile Polyposis Syndrome-Hereditary Hemorrhagic Telangiectasia due to SMAD4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25931195" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence of thoracic aortopathy in patients with juvenile Polyposis Syndrome-Hereditary Hemorrhagic Telangiectasia due to SMAD4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25645574" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33097490" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A Variant.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
